Rare diseases
Investigational molecules
Locations
Back to Belgium20 clinical trials in Libramont-Chevigny, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer
BelgiumStudy of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer
BelgiumStudy Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments
BelgiumStudy of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression
BelgiumStudy of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer
BelgiumStudy on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment
BelgiumStudy Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer
BelgiumStudy of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation
BelgiumThe busiest research cities in the country
What the registry says about research in the country
In Libramont-Chevigny, Belgium, the three actively recruiting studies concentrate on neoplasms, addressing some of the most challenging solid‑tumor indications. Researchers are evaluating novel combination immunotherapies, genetic vaccine strategies, and targeted agents to improve outcomes for patients with advanced cancers.
These trials aim to demonstrate enhanced anti‑tumor activity, higher response rates, and longer survival compared with standard therapies, offering hope for patients facing limited treatment options.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
